Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin gene

Gene Therapy

Volumn 17, Issue 11, 2010, Pages 1355-1362

  Koppanati, B M ^a   Li, J ^b   Reay, D P ^a   Wang, B ^a   Daood, M ^c   Zheng, H ^a   Xiao, X ^b   Watchko, J F ^c   Clemens, P R ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Duchenne Gene Therapy; Muscle; Skeletal Dependovirus Fetal Research Muscular Dystrophy

Indexed keywords

DYSTROPHIN; PARVOVIRUS VECTOR; RECOMBINANT DYSTROPHIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DUCHENNE MUSCULAR DYSTROPHY; EMBRYO; FEMALE; FETUS; GENE THERAPY; GENE TRANSFER; MOUSE; MUSCLE REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CYTOMEGALOVIRUS; DEPENDOVIRUS; DYSTROPHIN; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; PHENOTYPE; PROMOTER REGIONS, GENETIC;

DEPENDOVIRUS; HUMAN HERPESVIRUS 5; MUS;

EID: 78149469593     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.84     Document Type: Article

References (46)

1. Emery AE. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1991; 1: 19-29.
2. Emery AEH, Muntoni F. Duchenne Muscular Dystrophy. Oxford Univ Press: Oxford, New York, 2003.
3. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006; 12: 787-789.
4. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10: 828-834.
5. Liu M, Yue Y, Harper SQ, Grange RW, Chamberlain JS, Duan D. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 2005; 11: 245-256.
6. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-Suzuki Y et al. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 2004; 10: 821-828.
7. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD. Antisense oligonucleotide-induced exon skipping restores dystro-phin expression in vitro in a canine model of DMD. Gene Therapy 2006; 13: 1373-1381.
8. Cerletti M, Negri T, Cozzi F, Colpo R, Andreetta F, Croci D et al. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Therapy 2003; 10: 750-757.
9. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21: 583-593.
10. Inagaki K, Fuess S, Storm TA, Gibson GA, McTiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45-53.
11. Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328.
12. Rodino-Klapac LR, Janssen PM, Montgomery CL, Coley BD, Chicoine LG, Clark KR et al. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy. J Transl Med 2007; 5: 45.
13. Emerson CP, Hauschka SD. Embryonic Origins of Skeletal Muscles. In: Engel AG, Franzini-Armstrong C (eds). Myology. McGraw-Hill: NewYork USA, 2004, pp 3-44.
14. Biressi S, Molinaro M, Cossu G. Cellular heterogeneity during vertebrate skeletal muscle development. Dev Biol 2007; 308: 281-293.
15. Buckingham M, Bajard L, Chang T, Daubas P, Hadchouel J, Meilhac S et al. The formation of skeletal muscle: from somite to limb. J Anat 2003; 202: 59-68.
16. Duxson MJ, Usson Y. Cellular insertion of primary and secondary myotubes in embryonic rat muscles. Development 1989; 107: 243-251.
17. Ontell M, Bourke D, Hughes D. Cytoarchitecture of the fetal murine soleus muscle. Am J Anat 1988; 181: 267-278.
18. Ontell M, Kozeka K. Organogenesis of the mouse extensor digitorum logus muscle: a quantitative study. Am J Anat 1984; 171: 149-161. (Pubitemid 14023405)
19. Ontell M, Kozeka K. The organogenesis of murine striated muscle: a cytoarchitectural study. Am J Anat 1984; 171: 133-148. (Pubitemid 14023404)
20. Waddington SN, Nivsarkar MS, Mistry AR, Buckley SM, Kemball-Cook G, Mosley KL et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood 2004; 104: 2714-2721.
21. Waddington SN, Buckley SM, Nivsarkar M, Jezzard S, Schneider H, Dahse Tet al. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor. Blood 2003; 101: 1359-1366.
22. Sabatino DE, Mackenzie TC, Peranteau W, Edmonson S, Campagnoli C, Liu YL et al. Persistent expression of hF IX After tolerance induction by in utero or neonatal administration of AAV-1-F IX in hemophilia B mice. Mol Ther 2007; 15: 1677-1685.
23. Huard J, Feero WG, Watkins SC, Hoffman EP, Rosenblatt DJ, Glorioso JC. The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers. J Virol 1996; 70: 8117-8123.
24. Reay DP, Bilbao R, Koppanati BM, Cai L, O'Day TL, Jiang Z et al. Full-length dystrophin gene transfer to the mdx mouse in utero. Gene Therapy 2008; 15: 531-536.
25. Koppanati BM, Li J, Xiao X, Clemens PR. Systemic delivery of AAV8 in utero results in gene expression in diaphragm and limb muscle: treatment implications for muscle disorders. Gene Therapy 2009; 16: 1130-1137.
26. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002; 82: 291-329.
27. Rando TA. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 2001; 24: 1575-1594.
28. Torres LF, Duchen LW. The mutant mdx: inherited myopathy in the mouse Morphological studies of nerves, muscles and end-plates. Brain 1987; 110(Part 2): 269-299.
29. Bockhold KJ, Rosenblatt JD, Partridge TA. Aging normal and dystrophic mouse muscle: analysis of myogenicity in cultures of living single fibers. Muscle Nerve 1998; 21: 173-183.
30. Watchko JF, Johnson BD, Gosselin LE, Prakash YS, Sieck GC. Age-related differences in diaphragm muscle injury after lengthening activations. J Appl Physiol 1994; 77: 2125-2133.
31. Watchko JF, O'Day TL, Hoffman EP. Functional characteristics of dystrophic skeletal muscle: insights from animal models. J Appl Physiol 2002; 93: 407-417.
32. Karolewski BA, Wolfe JH. Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII. Mol Ther 2006; 14: 14-24.
33. Shen JS, Meng XL, Maeda H, Ohashi T, Eto Y. Widespread gene transduction to the central nervous system by adenovirus in utero: implication for prenatal gene therapy to brain involvement of lysosomal storage disease. J Gene Med 2004; 6: 1206-1215.
34. Seppen J, van der Rijt R, Looije N, van Til NP, Lamers WH, Oude Elferink RP. Long-term correction of bilirubin UDPglucuronyl-transferase deficiency in rats by in utero lentiviral gene transfer. Mol Ther 2003; 8: 593-599.
35. Han XD, Lin C, Chang J, Sadelain M, Kan YW. Fetal gene therapy of alpha-thalassemia in a mouse model. Proc Natl Acad Sci USA 2007; 104: 9007-9011.
36. Larson JE, Morrow SL, Happel L, Sharp JF, Cohen JC. Reversal of cystic fibrosis phenotype in mice by gene therapy in utero. Lancet 1997; 349: 619-620.
37. Rucker M, Fraites Jr TJ, Porvasnik SL, Lewis MA, Zolotukhin I, Cloutier DA et al. Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. Development 2004; 131: 3007-3019.
38. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16: 1073-1080.
39. Ziegler RJ, Bercury SD, Fidler J, Zhao MA, Foley J, Taksir TV et al. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. Hum Gene Ther 2008; 19: 609-621.
40. Sun B, Zhang H, Franco LM, Young SP, Schneider A, Bird A et al. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 2005; 11: 57-65.
41. Qiao C, Li J, Jiang J, Zhu X, Wang B, Li J et al. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 2008; 19: 241-254.
42. Wang B, Li J, Qiao C, Chen C, Hu P, Zhu X et al. A canine minidystrophin is functional and therapeutic in mdx mice. Gene Therapy 2008; 15: 1099-1106.
43. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
44. Li J, Samulski RJ, Xiao X. Role for highly regulated rep gene expression in adeno-associated virus vector production. J Virol 1997; 71: 5236-5243.
45. Bilbao R, Reay DP, Wu E, Zheng H, Biermann V, Kochanek S et al. Comparison of high-capacity and first-generation adeno-viral vector gene delivery to murine muscle in utero. Gene Therapy 2005; 12: 39-47.
46. Lu QL, Partridge TA. A new blocking method for application of murine monoclonal antibody to mouse tissue sections. J Histochem Cytochem 1998; 46: 977-984.